Editas Medicine
EDIT· Manufacturing· Fiscal year ends in December
Gilmore O’Neill, M.B., M.M.Sc. is the CEO of Editas Medicine and was paid $2.4M in FY2025 (Dec), down 54%.
Executives3
See all- 1Gilmore O’Neill, M.B., M.M.Sc.President and Chief Executive OfficerFY2025
- 2Linda C. Burkly, Ph.D.Executive Vice President and Chief Scientific OfficerFY2025
- 3Amy ParisonSenior Vice President and Chief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allEditas Medicine paid its 3 named executives $4.4M in total in FY2025 (Dec). CEO Gilmore O’Neill, M.B., M.M.Sc. was paid $2.4M of that.
| Name | |||
|---|---|---|---|
| Gilmore O’Neill, M.B., M.M.Sc.President and Chief Executive Officer | |||
| Linda C. Burkly, Ph.D.Executive Vice President and Chief Scientific Officer | Not disclosed | ||
| Amy ParisonSenior Vice President and Chief Financial Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers20
See allThe FY2025 (Dec) proxy of Editas Medicine names 20 peer companies for pay. Among Editas Medicine and these peers, CEO pay was 5th highest of 7 and total shareholder return was 6th highest of 7.
5th highest of 7in Editas Medicine and its pay peers, FY2025 (Dec) by CEO pay:
6th highest of 7in Editas Medicine and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board4
See all- Andrew J. HirschDirector · 8 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
- David ScaddenDirector · 6 yr on the boardIndependentCompensation—Paid as an executive
- Gilmore O’NeillDirector · 3 yr on the boardNot independent—Paid as an executive
- Elliott LevyDirector · 2 yr on the boardIndependentAudit—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 9, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 15, 2025 | FY2024 |
| Annual report | 10-K | Mar 5, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 16, 2024 | FY2023 |
| Annual report | 10-K | Feb 28, 2024 | FY2023 |
